2016
DOI: 10.1097/pas.0000000000000663
|View full text |Cite
|
Sign up to set email alerts
|

Unusual Mismatch Repair Immunohistochemical Patterns in Endometrial Carcinoma

Abstract: Universal screening for Lynch syndrome through mismatch repair (MMR) immunohistochemistry (IHC) on tumor samples has brought to light several heterogenous MMR staining patterns. At our institution, a prospective study of universal Lynch syndrome screening using MMR IHC on 125 endometrial cancers (EC) led to the identification of subclonal loss of MMR protein expression within the tumor (n=9). We also interrogated the MMR staining patterns in MMR-deficient EC with concurrent endometrial intraepithelial neoplasi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
81
0
1

Year Published

2017
2017
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 79 publications
(85 citation statements)
references
References 44 publications
3
81
0
1
Order By: Relevance
“…Intratumoral heterogeneity of MMR status has been described in some cases of colorectal and endometrial cancer but has so far not been analyzed in pancreatic adenocarcinoma. [26][27][28][29][30] To learn more on MSI heterogeneity in pancreatic cancer, a cohort of 597 operated pancreatic cancers was screened by IHC for loss of the MMR proteins MLH1, PMS2, MSH2, and/or MSH6 on a tissue microarray (TMA). Cases with suspected MSI were further analyzed by PCR and repeated IHC on large sections followed by a thorough analysis of all available cancer-containing tissue blocks for possible intratumoral heterogeneity.…”
mentioning
confidence: 99%
“…Intratumoral heterogeneity of MMR status has been described in some cases of colorectal and endometrial cancer but has so far not been analyzed in pancreatic adenocarcinoma. [26][27][28][29][30] To learn more on MSI heterogeneity in pancreatic cancer, a cohort of 597 operated pancreatic cancers was screened by IHC for loss of the MMR proteins MLH1, PMS2, MSH2, and/or MSH6 on a tissue microarray (TMA). Cases with suspected MSI were further analyzed by PCR and repeated IHC on large sections followed by a thorough analysis of all available cancer-containing tissue blocks for possible intratumoral heterogeneity.…”
mentioning
confidence: 99%
“…27 Although the majority of the indeterminate staining has been described in CRC, it has also been well documented in EC with more heterogeneity in the staining pattern, and subclonal loss as being the most frequent finding. [28][29][30][31] Indeterminate MMR staining in not unexpected because some gene mutations can be associated with intact protein expression, albeit a dysfunctional one, that can be detected by routine IHC. 8,32 Nontruncating point mutations or mutations in the noncoding region can also result in loss of enzymatic function with preservation of the defective protein that can cause weak staining.…”
Section: Discussionmentioning
confidence: 99%
“…The few available studies describing MSI in cohorts of NETs are basically limited to pancreatic primaries with reported frequencies between 10% (5/48) and 33% (18/55) by PCR-based methods [7,8]. Intratumoral heterogeneity of MSI-a potential strong confounder for molecular based treatments-has been observed in several cancer types, including colorectal cancer [9][10][11][12][13]. However, intratumoral heterogeneity of MSI in neuroendocrine neoplasms has not been evaluated so far.…”
Section: Introductionmentioning
confidence: 99%